Literature DB >> 23190429

Dermal equivalents in oncology: benefit of one-stage procedure.

Julien Pauchot1, Ahmed Elkhyat, Gwenael Rolin, Sophie Mac, Anne Grumblat, Arnaud Fotso, Philippe Humbert, Yves Tropet.   

Abstract

BACKGROUND: In oncology, dermal equivalent may be indicated to cover losses of substance related to skin tumors or after the removal of skin flaps.
OBJECTIVE: To report our experience of two dermal equivalents, Matriderm 1 mm with a one-stage graft (DE1) and Integra DL with a two-stage graft (DE2) in oncology. PATIENTS AND
METHOD: Retrospective, single-center study involving 16 patients.
RESULTS: Sixteen patients received dermal equivalents as an alternative to flaps (7 cases), over tendinous areas (7 cases), and for cosmetic purposes (2 cases). Twelve patients received DE1 and four DE2. Wound healing times with DE1 were 4 weeks less than those with DE2. Three cases of infection were noted with DE2. The use of dermal equivalents as an alternative to skin flaps was effective, and no adhesions were found over the tendinous areas.
CONCLUSION: The learning curve, the two-stage graft required with DE2, and not using a vacuum-assisted closure system can explain the high infection rate. The use of dermal equivalents is particularly indicated in the treatment of skin defect in oncology. The possibility of a one-stage graft with DE1 and combination with negative pressure therapy is beneficial.
© 2012 by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23190429     DOI: 10.1111/dsu.12044

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  3 in total

1.  Artificial dermis (Matriderm®) followed by skin graft as an option in dermatofibrosarcoma protuberans with complete circumferential and peripheral deep margin assessment.

Authors:  Eduardo Bertolli; Mariane Campagnari; André S Molina; Mariana P Macedo; Clovis A L Pinto; Isabela W Cunha; João P Duprat Neto
Journal:  Int Wound J       Date:  2013-09-19       Impact factor: 3.315

Review 2.  Dermal skin substitutes for upper limb reconstruction: current status, indications, and contraindications.

Authors:  Shady A Rehim; Maneesh Singhal; Kevin C Chung
Journal:  Hand Clin       Date:  2014-05       Impact factor: 1.907

Review 3.  Skin cancers and dermal substitutes: Is it safe? Review of the literature and presentation of a 2-stage surgical protocol for the treatment of non-melanoma skin cancers of the head in fragile patients.

Authors:  Marco Marcasciano; Marco Mazzocchi; Juste Kaciulyte; Noemi Spissu; Donato Casella; Diego Ribuffo; Luca Andrea Dessy
Journal:  Int Wound J       Date:  2018-06-04       Impact factor: 3.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.